RxDoctor Payments Data

Ahmed Souka, MD

Interventional Cardiology · Topeka, KSNPI 1790154185

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Shockwave Medical, Inc at 25.3% of the total.

$37,044in general payments, 2019–2025

Across 235 payments — averaging $157.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$9K
  • Edwards Lifesciences$8K
  • Boston Scientific$6K
  • Angiodynamics, Inc.$4K
  • Penumbra, Inc.$3K
  • Abbott$2K
  • plus $5K from 18 others

What the payments were for

  • Speaking & faculty fees$6,60018%
  • Grants$3491%
  • Travel & lodging$18,92751%
  • Food & beverage$10,94830%
  • Education$2201%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,044 in reported general payments places this provider in the 85th percentile of 55 interventional cardiology providers in Kansas.

See all interventional cardiology providers in Kansas

Medicare billing

Part B allowed, 2024
$136,803
Medicare patients
283
Services billed
1,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$29,657
XareltoRivaroxaban20$18,334
Atorvastatin Calcium114$851
Isosorbide Mononitrate ErIsosorbide Mononitrate47$491
Metoprolol Succinate46$457
Pravastatin Sodium24$400
Amlodipine Besylate71$268
Spironolactone15$246
Metoprolol Tartrate65$230
Losartan Potassium35$227
Nitroglycerin15$185
ClopidogrelClopidogrel Bisulfate18$180
Rosuvastatin Calcium24$165
Furosemide31$117
Carvedilol41$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$29,65736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 interventional cardiology providers in Kansas.

Other interventional cardiology in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →